-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $46

Benzinga·09/09/2026 13:19:58
Listen to the news
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.